고지혈증 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 약물 분류별, 적응증별, 투여 경로별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

Antihyperlipidemic Drugs Market Summary

The global antihyperlipidemic drugs market size was valued at USD 14.3 billion in 2025 and is projected to grow from USD 15.0 billion in 2026 to USD 22.0 billion by 2033, at a CAGR of 5.6% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The market is supported by the ongoing need to manage elevated LDL cholesterol and triglyceride levels and to reduce the risk of cardiovascular disease.

Statins remain the main treatment option because of their established use, availability of generic products, and role in long-term cholesterol management. However, treatment is expanding beyond statins as patients with cardiovascular risk may require additional LDL-lowering therapies such as ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran. The market also includes therapies for high triglyceride levels, including fibrates and prescription omega-3 products. Growing focus on lipid testing, earlier treatment, and management of patients who do not achieve adequate lipid control with statins is supporting demand for combination and non-statin therapies. Treatment decisions are increasingly based on overall cardiovascular risk, LDL-C levels, and patient-specific factors, supporting continued use of both established and newer antihyperlipidemic drugs.

Global Antihyperlipidemic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antihyperlipidemic drugs market report based on drug class, indication, route of administration, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
• Statins
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• ATP-Citrate Lyase (ACL) Inhibitors
• Fibrates
• Bile Acid Sequestrants
• Omega-3 Fatty Acid Products
• Niacin
• Combination Antihyperlipidemic Drugs
• Others
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Hypercholesterolemia
• Hypertriglyceridemia
• Mixed Dyslipidemia
• Others
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Subcutaneous
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Mail-Order / Online Pharmacies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antihyperlipidemic Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Antihyperlipidemic Drugs Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2025 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
• 4.4. Statins
  • 4.4.1. Statins Market, 2021 - 2033 (USD Billion)
• 4.5. Cholesterol Absorption Inhibitors
  • 4.5.1. Cholesterol Absorption Inhibitors Market, 2021 - 2033 (USD Billion)
• 4.6. PCSK9 Inhibitors
  • 4.6.1. PCSK9 Inhibitors Market, 2021 - 2033 (USD Billion)
• 4.7. ATP-Citrate Lyase (ACL) Inhibitors
  • 4.7.1. ATP-Citrate Lyase (ACL) Inhibitors Market, 2021 - 2033 (USD Billion)
• 4.8. Fibrates
  • 4.8.1. Fibrates Market, 2021 - 2033 (USD Billion)
• 4.9. Bile Acid Sequestrants
  • 4.9.1. Bile Acid Sequestrants Market, 2021 - 2033 (USD Billion)
• 4.10. Omega-3 Fatty Acid Products
  • 4.10.1. Omega-3 Fatty Acid Products Market, 2021 - 2033 (USD Billion)
• 4.11. Niacin
  • 4.11.1. Niacin Market, 2021 - 2033 (USD Billion)
• 4.12. Combination Antihyperlipidemic Drugs
  • 4.12.1. Combination Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
• 4.13. Others
  • 4.13.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Antihyperlipidemic Drugs Market: Indication Business Analysis

• 5.1. Indication Market Share, 2025 & 2033
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
• 5.4. Hypercholesterolemia
  • 5.4.1. Hypercholesterolemia Market, 2021 - 2033 (USD Billion)
• 5.5. Hypertriglyceridemia
  • 5.5.1. Hypertriglyceridemia Market, 2021 - 2033 (USD Billion)
• 5.6. Mixed Dyslipidemia
  • 5.6.1. Mixed Dyslipidemia Market, 2021 - 2033 (USD Billion)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Antihyperlipidemic Drugs Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
• 6.4. Oral
  • 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
• 6.5. Subcutaneous
  • 6.5.1. Subcutaneous Market, 2021 - 2033 (USD Billion)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Antihyperlipidemic Drugs Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.5. Specialty Pharmacies
  • 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.6. Retail Pharmacies
  • 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.7. Mail-Order / Online Pharmacies
  • 7.7.1. Mail-Order / Online Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.8. Others
  • 7.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Antihyperlipidemic Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Antihyperlipidemic Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.5. Europe
  • 8.5.1. Europe Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Amgen
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Merck & Co.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Sanofi
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Regeneron
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Novartis
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AstraZeneca
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Esperion Therapeutics
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Viatris
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives